This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
Pharmacy- and manufacturer-neutral approach offers members access to therapeutically equivalent, lower cost alternativesSAN DIEGO--(BUSINESS WIRE)--MedImpact Healthcare Systems, the nation’s largest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback